Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2011

View Archived Issues

AMG-386 does not improve efficacy of CX combination in gastroesophageal adenocarcinoma

BI-2536 shows potential in models of osteosarcoma

Escitalopram is safe and reduces menopausal hot flashes

Phase I trial assesses temsirolimus/sorafenib combination in HCC

Genome analyses identify distinct loci for CAD and for myocardial infarction in CAD

Kyowa Hakko Kirin and Amgen collaborate on AMG-827

FDA refuses to file Gilead's Truvada/TMC-278 NDA for HIV-1

Serum level of angiogenin-directed IgM antibodies as a biomarker of response to osteosarcoma therapy

New sodium channel blockers presented

New protein kinase inhibitors described by sanofi-aventis

New inhibitors of serine/threonine-protein kinase mTOR claimed

ASSERT trial data suggest potential of RVX-208 in Alzheimer's disease

FDA clears clinical testing of AREVA's alpha radioimmunotherapy involving 212Pb

ChemoCentryx begins phase I trial of CCX-832 under alliance with GSK

Sunshine Biopharma and Binghamton University sign agreement for Adva-27a

New inhibitors discovered of PI3K-alpha/mTOR/TNF-alpha/IL-6

NIH funds AndroScience's development of AR degradation enhancer for SBMA

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Enrollment begins in phase IIb RX-10100 trial in major depressive disorder

Chugai Pharma files for new indication of Pegasys

MBL-HCV1 enters phase II trial to prevent HCV reinfection in liver transplant recipients

GSK receives FDA complete response letter regarding Avodart sNDA

Anadys begins dosing in phase IIb ANA-598 trial in hepatitis C

AB Science initiates phase III masitinib study in severe asthma

Ligand Pharma acquires CyDex Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...